WO2005056754A3 - Compositions and methods to reduce mutagenesis - Google Patents

Compositions and methods to reduce mutagenesis Download PDF

Info

Publication number
WO2005056754A3
WO2005056754A3 PCT/US2004/039064 US2004039064W WO2005056754A3 WO 2005056754 A3 WO2005056754 A3 WO 2005056754A3 US 2004039064 W US2004039064 W US 2004039064W WO 2005056754 A3 WO2005056754 A3 WO 2005056754A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
achaogens
mutagenesis
inhibition
Prior art date
Application number
PCT/US2004/039064
Other languages
French (fr)
Other versions
WO2005056754A2 (en
Inventor
Floyd Romesberg
Nathaniel E David
Ryan Cirz
Original Assignee
Scripps Research Inst
Achaogen Inc
Floyd Romesberg
Nathaniel E David
Ryan Cirz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Achaogen Inc, Floyd Romesberg, Nathaniel E David, Ryan Cirz filed Critical Scripps Research Inst
Priority to JP2006541583A priority Critical patent/JP2007521329A/en
Priority to EP04817866A priority patent/EP1689852A4/en
Priority to CA002544018A priority patent/CA2544018A1/en
Publication of WO2005056754A2 publication Critical patent/WO2005056754A2/en
Publication of WO2005056754A3 publication Critical patent/WO2005056754A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides methods and compositions for inhibition of drug resistance. The invention generally involves compositions that comprise achaogens, agents that inhibit a mutational process, and administration of achaogens to inhibit evolution of drug resistance. In one embodiment, the invention provides methods and compositions for inhibition of antibiotic resistance.
PCT/US2004/039064 2003-06-26 2004-11-19 Compositions and methods to reduce mutagenesis WO2005056754A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006541583A JP2007521329A (en) 2003-11-19 2004-11-19 Compositions and methods for reducing mutagenesis
EP04817866A EP1689852A4 (en) 2003-06-26 2004-11-19 Compositions and methods to reduce mutagenesis
CA002544018A CA2544018A1 (en) 2003-11-19 2004-11-19 Compositions and methods to reduce mutagenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71800203A 2003-11-19 2003-11-19
US60/608,949 2003-11-19

Publications (2)

Publication Number Publication Date
WO2005056754A2 WO2005056754A2 (en) 2005-06-23
WO2005056754A3 true WO2005056754A3 (en) 2006-08-17

Family

ID=34677079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/039064 WO2005056754A2 (en) 2003-06-26 2004-11-19 Compositions and methods to reduce mutagenesis

Country Status (1)

Country Link
WO (1) WO2005056754A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8889187B2 (en) 2000-02-24 2014-11-18 Shionogi Inc. Once a day amoxicillin product comprising immediate and delayed release dosage forms
US9144548B2 (en) 2003-08-12 2015-09-29 Shionogi Inc. Antibiotic product, use and formulation thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
EP1871910A4 (en) * 2005-04-05 2009-07-29 Scripps Research Inst Compositions and methods for enhancing drug sensitivity and treating drug resistant infections an diseases
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
KR101781907B1 (en) 2008-10-31 2017-09-26 얀센 바이오테크 인코포레이티드 Fibronectin type iii domain based scaffold compositions, methods and uses
WO2011039382A1 (en) 2009-10-02 2011-04-07 Oslo Universitetssykehus Hf Antibacterial polypeptides and use thereof
US9393250B2 (en) 2012-04-12 2016-07-19 University Of Saskatchewan Phthalocyanine compounds useful as RecA inhibitors and methods of using same
CN113462711B (en) * 2021-07-01 2022-06-14 苏州大学 Screening system, construction method and application of mycobacterium tuberculosis protein intron splicing inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410514B1 (en) * 1997-05-19 2002-06-25 The Johns Hopkins University Tissue specific prodrug

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410514B1 (en) * 1997-05-19 2002-06-25 The Johns Hopkins University Tissue specific prodrug

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARUNAN C. ET AL: "Solid-phase synthesis of hydrophobic peptides on 1,6-hexanediol diacrylate crosslinked poly-styrene resin: comparison with Merrifield resin", PROTEIN AND PEPTIDE LETTERS, vol. 6, no. 6, 1999, pages 391 - 398, XP008071097 *
ILLENBERGER S. ET AL: "The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease", MOLECULAR BIOLOGY OF THE CELL, vol. 9, June 1998 (1998-06-01), pages 1495 - 1512, XP003001888 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889187B2 (en) 2000-02-24 2014-11-18 Shionogi Inc. Once a day amoxicillin product comprising immediate and delayed release dosage forms
US9144548B2 (en) 2003-08-12 2015-09-29 Shionogi Inc. Antibiotic product, use and formulation thereof
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products

Also Published As

Publication number Publication date
WO2005056754A2 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
WO2004075832A3 (en) Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP2338490A3 (en) Combinations useful for the treatment of neuronal disorders
WO2004113275A3 (en) Methods and compositions for treating amyloid-related diseases
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2006044505A3 (en) Compounds for nonsense suppression, and methods for their use
MY143795A (en) Tetrahydropyridoindole derivatives
WO2003064431A3 (en) Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
IL220480A0 (en) 1-benzyl-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors , preparation method thereof, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
TW200507830A (en) Bronchodilating β -agonist compositions and methods
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
DE602005022613D1 (en) 2,3,4-substituierte cyclopentanone als therapeutische mittel
EP1638938A4 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2005056754A3 (en) Compositions and methods to reduce mutagenesis
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2005000192A3 (en) Glycogen synthase kinase-3 inhibitors
MY141743A (en) 3h-quinazolin-4-one derivatives
WO2001052855A3 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
TW200733963A (en) Cough inhibitor
WO2004087066A3 (en) Hif-1 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2544018

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004817866

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006541583

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2004817866

Country of ref document: EP